Caron A. Jacobson, MD, Dana-Farber Cancer Institute
Advertisement
Articles by Caron A. Jacobson, MD, Dana-Farber Cancer Institute
Advertisement
Latest Updated Articles
CAR T for R/R FL: Treatment ConsiderationsPublished: April 19th 2021 | Updated:
Novel Therapies for R/R Follicular LymphomaPublished: April 19th 2021 | Updated:
Treating Follicular Lymphoma With Early ProgressionPublished: April 5th 2021 | Updated:
Emerging Therapies for R/R Follicular LymphomaPublished: April 5th 2021 | Updated:
R2 Regimen for R/R Follicular LymphomaPublished: March 15th 2021 | Updated:
Role of Rebiopsy in R/R Follicular LymphomaPublished: March 1st 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5